BIOTHERAPEUTIC CASE STUDY

Immune Design and Sanofi

Two collaboration and license agreements were signed between Immune Design and Sanofi after the initial equity investment made by Sanofi Ventures. The first was to use Immune Design’s GLAASTM discovery platform and the second was to develop best in class Herpes Simplex Virus vaccines (HSV). These agreements are still active and represent Sanofi Ventures achieving our strategic mandate and vision to be a preferred strategic investor for early stage companies.

Immune Design approached Sanofi Ventures for its Series C financing in 2013. As part of the Sanofi Ventures diligence process as a strategic investor, three groups within Sanofi, including the Immuno-Allergy team and Sanofi Pasteur, considered the early stage opportunity. With strong internal endorsement from these groups, Sanofi Ventures joined top tier venture investors (The Column Group, Topspin Partners, Versant Ventures, Alta Partners, Osage Venture Partners and Proquest Investments) and invested in Immune Design in October 2013.
Subsequently, the company initiated a number of Phase I clinical trials and successfully completed an IPO (NASDAQ:IMDZ) to which Sanofi Ventures also participated. In August 2014 and October 2014 respectively, a license agreement was executed between Immune Design and Sanofi to develop new therapeutics to treat food allergies using Immune Design’s GLAASTMdiscovery platform (press release) and a collaboration agreement was signed between Immune Design and Sanofi to develop first in class HSV vaccines (press release).

“Your involvement as an investor and foresight as to the synergies between both groups have helped to achieve this important collaboration around the GLAASTM technology,” said Carlos Paya, President & CEO of Immune Design.


DIGITAL HEALTH CASE STUDY

Science 37 and Sanofi

A collaboration agreement was signed between Science 37 and Sanofi to launch virtual clinical trials after the initial equity investment made by Sanofi Ventures. This collaboration is an example of Sanofi Ventures achieving our strategic mandate and vision to be a preferred strategic investor for digital health companies.

Science 37, a technology-enabled clinical research company, connected with Sanofi Ventures during its Series B financing in 2016. Through a process of joint diligence with the Clinical Operations and Digital Health teams, Sanofi Ventures evaluated Science 37’s solution to be best in class and also confirmed high strategic interest from these teams. As a result, Sanofi Ventures joined top digital health investors (Redmile Group, Lux Capital, dRx Capital) to invest in Science 37 in September 2016.

Sanofi initiated a partnership discussion with Science 37, which was facilitated by Sanofi Ventures’ relationship-building as an investor. In March 2017, Sanofi signed a broad collaboration with Science 37 to use its MetasiteTM Model and NORA in clinical trials across the U.S. with plans to expand internationally in the future (press release). Subsequently, Sanofi Ventures also participated in Science 37’s series C financing in April 2017 alongside Google Ventures, Glynn Capital, Amgen, and other insiders. The successful collaboration between Science 37 and Sanofi illustrates the nurturing of relationships between the two companies initiated by the equity investment of Sanofi Ventures.